Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMichele VenerusoSMSimona ManniRCRoberta Castriconi

Discussion

Loading...

Member takes

Overview

Preclinical results demonstrate effective CAR T-cell therapy in Acute Myeloid Leukemia, suggesting improved clinical outcomes by targeting leukemic stem cells.

Key Points

  • B7-H3-targeted CAR T-cell therapy effectively eradicated leukemic cells in vitro and in vivo.
  • At a 1:8 effector-to-target ratio, both CAR constructs led to significant reduction of THP-1 cells.
  • Assessment in a xenograft mouse model shows improved survival with CAR T-cell treatment.
  • Findings underscore the potential of this therapy to enhance outcomes in patients with Acute Myeloid Leukemia.

Cite This Study

Veneruso et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e144https://doi.org/10.1182/blood-2025-6095
View Full Paper
Ask AI
Bookmark
Share